Kolltan Pharmaceuticals Obtains $10,000,000 Series B Round
- Feed Type
- Link
http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=e03294f4-00a2-4dd3-8fa1-b8e405f5c81c&Preview=1 - Date
1/20/2010 - Company Name
Kolltan Pharmaceuticals - Mailing Address
300 George St New Haven, CT 06511 - Company Description
Kolltan is a development-stage company advancing therapeutics that target well-defined and validated molecular mechanisms of disease in areas of critical clinical need. - Website
http://www.kolltan.com - Transaction Type
Venture Equity - Transaction Amount
$10,000,000 - Transaction Round
Series B - Proceeds Purposes
Proceeds from these investments will be used to advance Kolltan’s therapeutic development pipeline. - M&A Terms
- Venture Investor
Celtic Therapeutics - Venture Investor
Tichenor Ventures
